June 2020 | Thought Leadership

Avara CEO Larry Lee on Outsourcing Trends & Company Highlights

Our CEO, Larry Lee, recently shared company highlights as well as his thoughts about trends in outsourcing and OSD & Steriles markets with Contract Pharma. 

May 2020 | Thought Leadership

Concentrating on Core OSD & Sterile Capabilities for Assured Client Success

With a solid base of oral solid dose and sterile manufacturing and packaging expertise that includes four state-of-the-art facilities delivering two billion patient doses annually, Avara Pharmaceutical Services has refocused to leverage its core ...

April 2020 | News

Avara Liscate Delivers Critical Care Drugs to Covid-19 Patients

The Covid-19 pandemic has created significant operational and logistical challenges for the pharmaceutical and healthcare industries worldwide.  Despite these challenges, across Avara, all facilities have been safely and successfully maintaining ...

March 2020 | News

Avara Offers Clients Virtual Visits to Solve Site Audit Challenges

As part of Avara’s Business Continuity actions, our goal is to support the delivery of all key project milestones, in order to minimize impact from Coronavirus (Covid-19) prevention measures. Where current restrictions may prevent a site visit or audit ...

February 2020 | News

2019: A Transformative Year for Avara, Paving the Way for a Strong 2020.

In 2019, Avara refocused the business on its core capabilities within Oral Solid Dose and Sterile and this resulted in an annual EBITDA of $30.7M (unaudited), at 15% on revenues of $203M, with positive contributions from every Avara facility.

January 2020 | News

Avara Liscate Facility Welcomes 2020 On a High!

Avara’s Liscate facility provides sterile manufacturing, fill-finish, and packaging services for supply to European, United States, Canadian, and Latin American markets.  During Q4 2019, the facility hosted the US FDA as part of a Pre-Approval Inspection ...